Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $6.52 in the prior trading day, Relay Therapeutics Inc (NASDAQ: RLAY) closed at $6.66, up 2.15%. In other words, the price has increased by $2.15 from its previous closing price. On the day, 1.46 million shares were traded. RLAY stock price reached its highest trading level at $6.97 during the session, while it also had its lowest trading level at $6.49.
Ratios:
Our goal is to gain a better understanding of RLAY by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 25.44 and its Current Ratio is at 25.44. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On April 19, 2023, Raymond James Upgraded its rating to Strong Buy which previously was Outperform but kept the price unchanged to $29.
On April 13, 2023, Raymond James started tracking the stock assigning a Outperform rating and target price of $29.Raymond James initiated its Outperform rating on April 13, 2023, with a $29 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 29 ’24 when Bergstrom Donald A sold 2,686 shares for $6.38 per share. The transaction valued at 17,137 led to the insider holds 527,427 shares of the business.
Catinazzo Thomas sold 1,695 shares of RLAY for $10,814 on Apr 29 ’24. The Chief Financial Officer now owns 339,803 shares after completing the transaction at $6.38 per share. On Apr 29 ’24, another insider, Adams Brian, who serves as the Chief Legal Officer of the company, sold 1,623 shares for $6.38 each. As a result, the insider received 10,355 and left with 325,767 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RLAY now has a Market Capitalization of 881351104 and an Enterprise Value of 177032368. For the stock, the TTM Price-to-Sale (P/S) ratio is 34.50 while its Price-to-Book (P/B) ratio in mrq is 1.13. Its current Enterprise Value per Revenue stands at 6.93 whereas that against EBITDA is -0.473.
Stock Price History:
The Beta on a monthly basis for RLAY is 1.68, which has changed by -0.40641713 over the last 52 weeks, in comparison to a change of 0.23568535 over the same period for the S&P500. Over the past 52 weeks, RLAY has reached a high of $13.32, while it has fallen to a 52-week low of $5.70. The 50-Day Moving Average of the stock is -17.95%, while the 200-Day Moving Average is calculated to be -27.68%.
Shares Statistics:
The stock has traded on average 1.22M shares per day over the past 3-months and 1433950 shares per day over the last 10 days, according to various share statistics. A total of 127.46M shares are outstanding, with a floating share count of 93.02M. Insiders hold about 29.71% of the company’s shares, while institutions hold 71.10% stake in the company. Shares short for RLAY as of 1713139200 were 10692091 with a Short Ratio of 8.77, compared to 1710460800 on 11812402. Therefore, it implies a Short% of Shares Outstanding of 10692091 and a Short% of Float of 10.39.
Earnings Estimates
Relay Therapeutics Inc (RLAY) is presently subject to a detailed evaluation by 10.0 analysts, each offering their unique perspectives on its market standing.On average, analysts expect EPS of -$0.71 for the current quarter, with a high estimate of -$0.63 and a low estimate of -$0.81, while EPS last year was -$0.78. The consensus estimate for the next quarter is -$0.74, with high estimates of -$0.64 and low estimates of -$0.86.
Analysts are recommending an EPS of between -$2.44 and -$3.33 for the fiscal current year, implying an average EPS of -$2.94. EPS for the following year is -$2.88, with 10.0 analysts recommending between -$2.31 and -$3.78.
